Neurofibromatosis Clinical Trials

A listing of Neurofibromatosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 31 clinical trials
DPCP to Treat Cutaneous Neurofibromas Associated With NF1

Neurofibromatosis type 1 (NF1) is the most common genetic tumor predisposition syndrome, affecting up to 1 in 2500 individuals. Cutaneous neurofibromas are benign with self-limited growth

  • 0 views
  • 07 Oct, 2022
  • 1 location
A Phase I/II, Single-Arm, Open Label Study to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With Neurofibromatosis Type 1 (NF1) Related Symptomatic, Inoperable Plexiform Neurofibromas (PN) (SPRINKLE) (SPRINKLE)

This study is designed to define a dosing regimen and assess the pharmacokinetics(PK) and safety of the granule formulation; the study will also include descriptive analyses of exploratory efficacy endpoints. The study will inform the benefit risk profile of the granule formulation in children aged ≥ 1 to < 7 …

  • 0 views
  • 13 Oct, 2022
  • 7 locations
  • 0 views
  • 25 Oct, 2022
  • 26 locations
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)

A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

dabrafenib
trametinib
  • 492 views
  • 29 Oct, 2022
  • 15 locations
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

neurofibromas. At Visit 1, the investigator will identify 10 Target cNFs that fulfil the enrollment criteria. The Target cNFs must be located on the subject's face, anterior trunk, or upper extremities. Two

  • 38 views
  • 07 Oct, 2022
  • 20 locations
Doxycycline Injection of Cutaneous Schwannoma in Neurofibromatosis Type 2

In this research study the investigators want to learn more about an alternate, local treatment for skin schwannomas. Specifically, local doxycycline intra-tumoral injection will be performed as a potential treatment for NF2-related skin schwannomas, ultimately reducing the risks and costs associated with standard surgical removal of such skin tumors if …

  • 0 views
  • 10 Oct, 2022
  • 1 location
A Phase I/II Study of the Cyclin-Dependent Kinase(CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type 1 (NF1) Related Atypical Neurofibromas

Background NF1 is a genetic disease that causes tumors called atypical neurofibromas. These tumors, which arise from nerves, can cause serious medical problems

dysplasia
gilbert disease
immunomodulators
ejection fraction
renal function
  • 0 views
  • 21 Oct, 2022
  • 1 location
Phase I/II Trial of PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)

. For Phase II, people ages 3 31 with a Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibroma (PN) that cannot be removed with surgery. Design

platelet count
corticosteroids
filgrastim
graft versus host disease
immunosuppressive agents
  • 48 views
  • 23 Oct, 2022
  • 1 location
Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1

This study has two primary objectives. The first is to determine if it is feasible and reliable for children and families with a diagnosis of Neurofibromatosis Type 1 (NF1) to use of blood

home blood pressure monitoring
  • 0 views
  • 07 Oct, 2022
  • 1 location
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas (POPLAR-NF2)

This is a parallel-group, two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.

  • 0 views
  • 04 Oct, 2022
  • 5 locations